TNFAIP3 and diffuse large B-cell lymphoma: EV-mediated transfer of miRNAs between diffuse large B-cell lymphoma (DLBCL) cells, such as miR-125b-5p targeting TNFAIP3, has specifically been demonstrated to reduce sensitivity to rituximab[29]; however, the mechanism is unclear.